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Each month, Chemistry & Biology Select highlights a selection of research reports recently pub-
lished in other journals. These highlights are a snapshot of interesting research done across the field
of chemical biology, and this month’s Select includes reports on imaging oxidative and nitrosative
stress to test drug toxicity, finding the Achilles’ heel of glioblastoma, developing improved zinc
finger recombinases, and linking iron metabolism and p53.Schematic representation of CF-SPN design (center) highlights
all the key features of the biosensor (the semiconducting polymer,
the H2O2 sensor, the ONOO
– sensor, and the liver targeting compo-
nent). Images of mice to the left and right show readouts of chemo-
luminescence and fluorescence channels upon acetaminophen
administration, respectively. Image courtesy of Adam Shuhendler.Imaging Liver under Stress as a
Window into Drug Toxicity
The liver is a chemical plant with an array of enzymes that
metabolize and detoxify the majority of compounds used as
drugs. Some of the liver enzymes catalyze reactions that
generate reactive metabolites and radical species, such as
the reactive oxygen species (ROS) and the reactive nitrogen
species (RNS). These byproducts of the drug metabolism
are the main cause of drug toxicity, a major clinical and regu-
latory concern; therefore, drug toxicity needs to be carefully
evaluated inethearly stagesofdrugdevelopment toeliminate
compound with high toxicity from the pipeline. One possible
way to make this assessment is to measure levels of liver
ROS and RNS in vivo upon administration of a specific drug.
Shuhendler et al. describe a sensor for simultaneous in vivo imaging of liver ROS and RNS via detection of H2O2 and
ONOO, respectively. The sensor uses semiconducting polymer nanoparticles (SPNs), which were in this case constructed
from near-infrared (NIR) fluorescent semiconducting polymer (PFODBT) and a galactosylated copolymer (PS-g-PEG-Gal),
where PS-g-PEG-Gal is used for hepatocyte targeting. The sensor also includes CPPO, a H2O2-responsive chemiluminescent
substrate, and IR775S, a RNS-responsive dye. The presence of ROS leads to an increase in chemiluminescence resonance
energy transfer (CRET) between the CPPO cleavage product and PFODBT, while the presence of RNS leads to a decrease
in fluorescence resonance energy transfer (FRET) between PFODBT and IR775S. In this way, CF-SPNs can be employed
to image both ROS and RNS using two separated optical channels. The authors validate the performance of CF-SPNs
in vitro and in vivo and show how CF-SPNs can be used to image damage caused by two currently used drugs, acetamino-
phen and isoniazid, in real time. The study provides the validation of the CF-SPNs as ROS and RNS biosensors that could
be used beyond the testing of drug toxicity in liver and highlights the promise of H2O2 and ONOO
 as biomarkers for early
evaluation of drug safety.
Shuhendler et al. (2014) Nat. Biotechnol. 32, 373-380.
Forcing Glioblastoma Cells to Burst
For patients, the diagnosis of glioblastomamultiforme (GBM) is currently a death sentence, as existing treatments can at best
extend lives by a couple of years. Unlike some other cancers, for which the hunt for a targeted therapy has resulted in several
lauded success stories, genetic changes found in GBM involve simultaneous perturbation to oncogenic, tumor suppressor,
and cell cycle regulation pathways, thwarting the target-based approach.
The report by Kitambi et al. may change all that. Starting from the idea that the sweeping genetic changes that occur in GBM
might endow glioblastoma cells (GCs) with unique pathways not present in other cell types, the authors perform a phenotypic
screen of more than 1300 compounds from NIH Diversity Set II to look for small molecules that cause GC cell death without
affectingembryonicstemcells or fibroblasts. Thebest performingcompound theauthorsdiscover containsaquinolone-alcohol
scaffold, and Kimabli et al. name it Vacquinol-1. Follow up examination of Vacquinol-1’s mechanism of action shows that it
induces an unconventional cell death pathway by initiating macropinocytosis, which eventually leads to the bursting of the
cytoplasmic membrane and necrotic-like cell death. The effect is specific for GCs and involves activation of MKK4, a member
of the MAP kinase kinase family. In addition to beginning to resolve the mechanistic details of Vacquinol-1 activity, the authors
perform SAR studies and document that quinolone core and 2-(4-chlorophenyl) functionality could be modified to improve
potency. Lastly, Kimabli et al. provide evidence that Vacquinol-1 in vivo activity mirrors the activity shown in vitro, and that
oral administration in a mouse model of GBM results in a decrease in disease progression and improved survival. Vacquinol-
1 appears to be a promising starting point for developing targeted therapy that exploits a point of vulnerability specific for GBM.
Kitambi et al. (2014). Cell. Published online April 10, 2014. http://dx.doi.org/10.1016/j.cell.2014.02.021.Chemistry & Biology 21, April 24, 2014 ª2014 Elsevier Ltd All rights reserved 431
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Genetic engineering efforts have relied heavily on the availability of the tools that enable genome manipulation, especially
those that result in targeted genetic modifications. One class of tools for targeted genetic engineering includes zinc
finger recombinases (ZFRs) that contain the catalytic domain of a member of the resolvase/invertase family of serine
recombinases and a custom-designed Cys2–His2 zinc-finger (ZF) domain. ZFRs thus combine the sequence-dependent
catalysis of recombinases with site-specific DNA recognition of ZF domains to achieve site-specific genetic engineering.
The main obstacle to widespread ZFR application is the level of off-target modifications when using heterodimeric ZFR
species.
Gaj et al. solve this problem by redesigning the recombinase dimer interface to favor heterodimer formation. The system on
which the authors focus is ZFRs containing Gin recombinases a and z. They start by rationally introducing specific mutations
within the region known to be critically involved in forming the dimer interface. Next, they employ directed evolution to
identify variants with enhanced heterodimerization efficiency, holding Gin a monomer constant and screening for Gin z
monomers with optimal complementarity. This strategy resulted in identification of a Gin z variant that exhibited 2000-fold
enhancement of activity on an asymmetric DNA target when used with Gin a than when applied on a symmetric DNA target
as a homodimer. The new ZFR heterodimer system exhibited improved specificity in mammalian cells as well as improved
specificity of targeted gene integration. Overall, the resulting ZFRs described by the authors have improved specificity and
reduced toxicity, which makes them an attractive genetic engineering tool and an alternative to more prominent tools like
ZFNs, TALENs, and CRISPR/Cas9 systems.
Gaj et al. (2014). J. Am. Chem. Soc. 136, 5047-5056.Tumor suppressor protein p53
shields cells from stress-induced
damage. Shen et al. demonstrate
that hemin, an iron containing
porphyrin, binds p53 and impedes
its protective activity. Thefindings
suggest a mechanistic link be-
tween iron metabolism and can-
cer. Image courtesy of Rong-gui
Hu and colleagues from Shanghai
Institute of Biological Sciences,
Chinese Academy of Sciences.
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Iron is an essential albeit potentially toxic cofactor critical for the folding and function of
numerous proteins. To ensure overall cellular well being, organisms ranging from bacteria
to human have evolved elaborate pathways to control iron metabolism and keep iron
levels in check. Deregulation of iron metabolism is a documented cause of a number of
human disorders, such as anemia, when iron levels are low, and cancer, when iron is present
in excess. The exact way in which iron might be involved in tumorigenesis is still an open
question.
In their new report, Shen et al. probe the link between tumor suppressor protein p53,
also known as the ‘‘guardian of the genome,’’ for its role in supporting genome stability,
and high levels of iron. They report that p53 protein levels decrease when mice are placed
on a high-iron diet or when levels of iron are increased due to genetic changes to iron
metabolism. Follow-up work reveals that p53 interacts directly with hemin, the Fe3+-bound
form of protoporphyrin IX, and that this interaction is critical for the observed effect of iron
on p53 levels. Shen et al. determine that p53 binds to hemin through its heme regulatory
motif (HRM) located within its DNA binding domain, and that hemin binding interferes
with p53-DNA binding. Additionally, hemin decreases p53 protein levels by inducing p53
nuclear export and increasing p53 proteasomal degradation in the cytosol. Lastly, the
authors show that p53 is critical for mediating the anticancer effects of an iron chelator,
deferoxamine (DFO), currently used as iron-deprivation-based chemotherapy. Overall,
this work highlights an important link between iron metabolism and p53 function, with
implications for future chemotherapy development and exploration of crosstalk between
iron metabolism and tumorigenesis.
Shen et al. (2014). Cell Reports. Published online March 27, 2014. http://dx.doi.org/
10.1016/j.celrep.2014.02.042.
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